Literature DB >> 9839699

In vitro activation of complement and contact system by lactic acidosis.

J Sonntag1, M Emeis, E Strauss, M Obladen.   

Abstract

The activation of complement and contact systems occurs in reperfusion injuries with initial tissue hypoxia, and lactic acidosis such as mycardial infarction and birth asphyxia. The aim of our experiment was the formal proof of activation by sole lactic acidosis. Lactic acid was added to blood and plasma samples from 10 healthy volunteers. C5a and factor XIIa were measured by EIA after incubation at 37 degrees C for 1 h. Both concentrations increased (P < 0.0001 by Friedman analysis) in blood and plasma samples with increasing amount of added lactic acid. Lactic acidosis can activate C5 from the complement system and factor XII from the contact system directly, even in the absence of cellular components.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9839699      PMCID: PMC1781817          DOI: 10.1080/09629359891388

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  13 in total

1.  Both plasma- and leukocyte-associated C5a are essential for assessment of C5a generation in vivo.

Authors:  G Hetland; O Moen; K Bergh; K Högäsen; C E Hack; T E Mollnes; E Fosse
Journal:  Ann Thorac Surg       Date:  1997-04       Impact factor: 4.330

2.  Regulation of the alternative pathway of complement by pH.

Authors:  Z Fishelson; R D Horstmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

3.  Activation of the classical complement pathway by BioRex-70.

Authors:  R J Vandenberg; S B Easterbrook-Smith
Journal:  Immunol Lett       Date:  1987-01       Impact factor: 3.685

4.  Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.

Authors:  C H Hammer; G Hänsch; H D Gresham; M L Shin
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

5.  An enzyme-linked immunosorbent assay (ELISA) for the measurement of activated factor XII (Hageman factor) in human plasma.

Authors:  R P Ford; M P Esnouf; A I Burgess; A Sarphie
Journal:  J Immunoassay       Date:  1996-05

Review 6.  Brain protection: physiological and pharmacological considerations. Part I: The physiology of brain injury.

Authors:  J Murdoch; R Hall
Journal:  Can J Anaesth       Date:  1990-09       Impact factor: 5.063

7.  Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion.

Authors:  G Horstick; A Heimann; O Götze; G Hafner; O Berg; P Böhmer; P Becker; H Darius; H J Rupprecht; M Loos; S Bhakdi; J Meyer; O Kempski
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

8.  Complement activation induced by human C-reactive protein in mildly acidic conditions.

Authors:  K Miyazawa; K Inoue
Journal:  J Immunol       Date:  1990-07-15       Impact factor: 5.422

9.  Contact activation during incubation of five different polyurethanes or glass in plasma.

Authors:  K W van der Kamp; K D Hauch; J Feijen; T A Horbett
Journal:  J Biomed Mater Res       Date:  1995-10

Review 10.  Lactic acidosis.

Authors:  B A Mizock
Journal:  Dis Mon       Date:  1989-04       Impact factor: 3.800

View more
  7 in total

1.  Streptococcus pyogenes Endopeptidase O Contributes to Evasion from Complement-mediated Bacteriolysis via Binding to Human Complement Factor C1q.

Authors:  Mariko Honda-Ogawa; Tomoko Sumitomo; Yasushi Mori; Dalia Talat Hamd; Taiji Ogawa; Masaya Yamaguchi; Masanobu Nakata; Shigetada Kawabata
Journal:  J Biol Chem       Date:  2017-01-30       Impact factor: 5.157

Review 2.  The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients.

Authors:  G S Gupta
Journal:  Inflammation       Date:  2022-05-19       Impact factor: 4.657

3.  [Biodegradable synthetic implant materials : clinical applications and immunological aspects].

Authors:  F Witte; T Calliess; H Windhagen
Journal:  Orthopade       Date:  2008-02       Impact factor: 1.087

4.  Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.

Authors:  Coen Maas; José W P Govers-Riemslag; Barend Bouma; Bettina Schiks; Bouke P C Hazenberg; Henk M Lokhorst; Per Hammarström; Hugo ten Cate; Philip G de Groot; Bonno N Bouma; Martijn F B G Gebbink
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

5.  In-vitro activation of complement system by lactic acidosis in newborn and adults.

Authors:  F Hecke; T Hoehn; E Strauss; M Obladen; J Sonntag
Journal:  Mediators Inflamm       Date:  2001-02       Impact factor: 4.711

Review 6.  Complement-Coagulation Cross-Talk: A Potential Mediator of the Physiological Activation of Complement by Low pH.

Authors:  Hany Ibrahim Kenawy; Ismet Boral; Alan Bevington
Journal:  Front Immunol       Date:  2015-05-06       Impact factor: 7.561

7.  Acidosis activates complement system in vitro.

Authors:  M Emeis; J Sonntag; C Willam; E Strauss; M M Walka; M Obladen
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.